Key statistics
As of last trade ADC Therapeutics SA (ADCT:NYQ) traded at 4.17, -13.13% below its 52-week high of 4.80, set on Oct 30, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 4.02 |
|---|---|
| High | 4.21 |
| Low | 3.94 |
| Bid | 4.17 |
| Offer | 4.20 |
| Previous close | 4.10 |
| Average volume | 846.62k |
|---|---|
| Shares outstanding | 123.88m |
| Free float | 105.21m |
| P/E (TTM) | -- |
| Market cap | 507.90m USD |
| EPS (TTM) | -1.51 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 18:32 GMT.
More ▼
- ADC Therapeutics to Participate in March Investor Conferences
- ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement
- ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
- $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
- ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
- ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
- ADC Therapeutics Announces New Employee Inducement Grant
- Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
- ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
- ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
More ▼
